000963 华东医药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入11,183,4514.17%43,612,01041,905,70740,623,78337,714,587
减:营业总成本9,992,8733.88%39,388,88137,493,02037,081,91534,568,570
    其中:营业成本7,387,4442.51%29,499,47927,988,54727,461,73225,682,497
               财务费用(4,725)-132.33%18,77322,26551,19078,257
               资产减值损失----(87,896)(41,006)(6,520)(3,822)
公允价值变动收益--------(13,756)28,469
投资收益(22,310)-47.66%(137,843)(129,191)(219,713)(141,560)
    其中:对联营企业和合营企业的投资收益(7,510)-73.42%(75,923)(68,453)(188,391)(115,619)
营业利润1,200,0335.99%4,107,8934,324,7373,452,9273,061,454
利润总额1,192,1947.90%4,016,4624,301,5143,465,9863,031,124
减:所得税费用195,0332.13%605,616807,328619,589498,499
净利润997,1619.10%3,410,8473,494,1862,846,3972,532,626
减:非控股权益(5,028)594.18%(3,489)(17,919)7,53633,411
股东净利润1,002,1899.56%3,414,3353,512,1052,838,8612,499,214

市场价值指针
每股收益 (元) *0.5729.40%1.9482.0051.6221.428
每股派息 (元) *----0.9300.9300.5800.290
每股净资产 (元) *14.6736.98%14.14513.14511.99710.592
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容